HR Business Partner – 80%–100% – gère RH sur trois unités – Vernier, Suisse; mobilité régulière sur plusieurs sites en Suisse

HR Business Partner – 80%–100% – gère RH sur trois unités – Vernier, Suisse; mobilité régulière sur plusieurs sites en Suisse HR Business Partner – 80% - 100% Miglior soccorso stradale della Svizzera Soccorso stradale per bici e e-bike Assistenza in caso di maltempo Assistenza in caso di soppressione dei mezzi pubblici Sconti e vantaggi riservati ai soci HR Business Partner – 80% - 100% Envie d’un rôle RH concret, proche du terrain et à fort impact ?Au sein de notre siège à Vernier, tu prends en main la gestion RH au sein de trois Unités et participes aux projets RH qui soutiennent la performance, l’engagement et l’évolution du TCS. ...

May 2, 2026

Ärztezentren Ostschweiz AG, Benken (SG), Prokuraänderung nach Ausscheiden Sonja Meury; Maurin Livio Manhart erhält Kollektivprokura zu zweien

Ärztezentren Ostschweiz AG, Benken (SG), Prokuraänderung nach Ausscheiden Sonja Meury; Maurin Livio Manhart erhält Kollektivprokura zu zweien Mutation Ärztezentren Ostschweiz AG, Benken (SG) Ärztezentren Ostschweiz AG, in Benken (SG), CHE-448.572.461, Aktiengesellschaft (SHAB Nr. 46 vom 09.03.2026, Publ. 1006590458). Ausgeschiedene Personen und erloschene Unterschriften: Meury, Sonja, von Jegenstorf, in Zürich, mit Kollektivprokura zu zweien. Eingetragene Personen neu oder mutierend: Manhart, Maurin Livio, von Quarten, in Zürich, mit Kollektivprokura zu zweien.

May 1, 2026

Semtech (International) AG, Rapperswil-Jona, Verwaltungsratswechsel; Moore neue Präsidentin Dhunaka Padula neue Unterschriftsberechtigte

Semtech (International) AG, Rapperswil-Jona, Verwaltungsratswechsel; Moore neue Präsidentin Dhunaka Padula neue Unterschriftsberechtigte Mutation Semtech (International) AG, Rapperswil-Jona Semtech (International) AG, in Rapperswil-Jona, CHE-104.805.486, Aktiengesellschaft (SHAB Nr. 197 vom 10.10.2024, Publ. 1006151012). Ausgeschiedene Personen und erloschene Unterschriften: Gutierrez, Jeffrey, französischer Staatsangehöriger, in Eschenbach SG, Präsident des Verwaltungsrates, mit Kollektivunterschrift zu zweien. Eingetragene Personen neu oder mutierend: Moore, Aishling, von Engelberg, in Richterswil, Präsidentin des Verwaltungsrates, mit Kollektivunterschrift zu zweien [bisher: Mitglied des Verwaltungsrates, mit Kollektivunterschrift zu zweien]; Dhunaka, Venkata Jamalaiah, amerikanischer Staatsangehöriger, in Oak Park (US), mit Kollektivunterschrift zu zweien; Padula, Ilaria, italienische Staatsangehörige, in Wängi, mit Kollektivunterschrift zu zweien.

May 1, 2026

Harald Thorstein steps down as Non-Executive Director, Odfjell Drilling Ltd, London; Board remains four non-exec directors.

Harald Thorstein steps down as Non-Executive Director, Odfjell Drilling Ltd, London; Board remains four non-exec directors. ODL - Directorate Change - Odfjell Drilling Odfjell Drilling Ltd (“Odfjell Drilling” or the “Company”, OSE:ODL), notes thatHarald Thorstein has informed the board of his decision to step down from hisrole as Non-Executive Director of Odfjell Drilling Ltd with effect from today,30 April 2026. Pursuant to the Company’s Bye-Laws, the resulting vacancy on the Board ofDirectors does not need to be filled and the Board will now consist of fournon-executive directors. ...

April 30, 2026

Alexander H. Lottis verlängert Vertrag als Geschäftsführer des Universitätsklinikums Ruppin-Brandenburg (ukrb) in Ostprignitz-Ruppin; Wirtschaftliche Stabilität bis Ende 2027

Alexander H. Lottis verlängert Vertrag als Geschäftsführer des Universitätsklinikums Ruppin-Brandenburg (ukrb) in Ostprignitz-Ruppin; Wirtschaftliche Stabilität bis Ende 2027 Vertrag von ukrb-Geschäftsführer bis 2031 verlängert / Landkreis Ostprignitz-Ruppin InformationenAktuelle MitteilungenThemen der WocheVeranstaltungenAktuelle BaustellenÖffentliche BekanntmachungenSatzungen - Richtlinien - Verordnungen - AllgemeinverfügungenBerichte - Planung - StatistikenStellenausschreibungen Satzungen - Richtlinien - Verordnungen - Allgemeinverfügungen Berichte - Planung - Statistiken Der Aufsichtsrat der PRO Klinik Holding GmbH hat den Vertrag von ukrb-Geschäftsführer Alexander H. Lottis vorfristig um fünf Jahre verlängert. Lottis wird das Universitätsklinikum Ruppin-Brandenburg (ukrb) damit bis 2031 leiten. ...

April 30, 2026

Polly Cooper, Clinical Development Function Head, UK; rejoined Novartis amid AI-driven transformation

Polly Cooper, Clinical Development Function Head, UK; rejoined Novartis amid AI-driven transformation Full Circle: A Story of Growth, Purpose and Coming Home to Novartis | Novartis People and Culture Full Circle: A Story of Growth, Purpose and Coming Home to Novartis Polly Cooper, Clinical Development Function Head, UK Apr 28, 2026 I had always dreamed of working with racehorses; however, my father encouraged me to stay at school and finish my A levels. So, I followed the sensible path: taking the exams, moving to Covent Garden, London, and starting work as an estate agent. I really loved that job yet a part of me never let go of the dream of becoming a jockey. So, I took a chance and started a job in racing based in Ascot, however it was not the career for me and I returned home six months later unsure of what would come next. As fate would have it, my uncle, a medic, was visiting from Australia. He had such fascinating stories of his work as a Diplomat - being in Tiananmen Square during the revolution and then in Red Square in China for the riots. He inspired me to open my mind to new possibilities. He was also the one who spotted an ad in the newspaper for a Lab Technician role at CibaGeigy and encouraged me to apply. I had no formal scientific qualifications, although I’d always loved science thanks to my unforgettable teachers who had brought it to life in school. I was convinced I wouldn’t be hired. I must have displayed something in those interviews, because to my amazement, a week before my 21st birthday I stepped into the labs as part of the formulation development team for over-the-counter medicines. It was exciting, energizing - and it felt like the start of a real career. As time went on, I noticed my colleagues had qualifications I didn’t yet hold. If I wanted to grow, I needed to invest in myself. Supported by the company, I spent one day a week studying for my Higher National Certificate in Pharmaceutical Science, and then for my Pharmacology degree. When CibaGeigy merged with Sandoz in 1996, I found myself part of the newly created Novartis - a turning point that opened doors into Clinical Pharmacology and later into a series of roles that shaped the career I’m so grateful for today. Support from colleagues and leaders who believed in me made everything possible, even my MBA sponsorship. I saw a company transformed - more focused, more technologically advanced, integrating AI into daily decision making and strengthening its identity as a pure-play innovative medicines company anchored in five core therapeutic areas. It felt like stepping back into the future. Polly , Clinical Development Function Head, UK Redundancy, Reinvention… and an Unexpected Homecoming More than a decade later, when Novartis closed the UK site in Horsham, I had the chance to relocate to Basel. But with a newborn at home, the timing just wasn’t right. I left and transitioned into a leadership role in Pharmaceutical Product Development (PPD) - fascinating work, fast-paced and deeply engaging. Yet I found myself missing something: the full picture of drug development that Novartis offered. Contract Research Organizations (CROs) taught me depth and speed. Whereas Novartis had always offered breadth, integration and the sense that all parts of the puzzle connected under one roof. In 2025 when the company I was working for restructured, I found myself looking ahead and asking myself what I truly wanted next. I knew I didn’t want ‘more of the same’ - I wanted growth, purpose, stretch. When I saw Novartis was hiring again in the UK, I applied. I didn’t get the first role - and that was humbling. It reminded me that Novartis truly attracts exceptional talent, and you need resilience and belief in yourself to put yourself amongst those people. Re- energised, I re-entered the process and was eventually rehired into my current role - and it genuinely felt like coming home. There were the familiar faces, some of the same projects, and the same culture of humanity that makes Novartis special. Yet I also saw a company transformed - more focused, more technologically advanced, integrating AI into daily decision making and strengthening its identity as a pure-play innovative medicines company anchored in five core therapeutic areas. It felt like stepping back into the future. What would I say to anyone thinking of returning to or joining Novartis? This place is extraordinary - not because of buildings or branding, it’s because it invests in people. When I left, I gained invaluable experience across other organizations. But coming back allowed me to channel everything I had learned into helping others with opportunities to grow. Novartis supported my education and development; now I get to pay it forward. If you’re considering returning as an alum - or joining for the first time - ask yourself: What energy will you bring? What curiosity drives you? How deeply do you care about people and patients? Where do you want your talent to make an impact? Because if you bring ability, agility and aspiration, this is a place where you can thrive - and help reimagine medicine for the world. Learn more about opportunities across R&D here: Career Search | Novartis ...

April 29, 2026

Hafid Rifi wird neuer CFO der LUKS Gruppe; übernimmt CFO-Position am 1. Juli 2026

Hafid Rifi wird neuer CFO der LUKS Gruppe; übernimmt CFO-Position am 1. Juli 2026 Hafid Rifi wird neuer CFO der LUKS Gruppe | Luzerner Kantonsspital Hafid Rifi wird neuer CFO der LUKS Gruppe Hafid Rifi wird neuer CFO der LUKS Gruppe Hafid Rifi ist Wirtschaftsprüfer, Steuerberater und hat einen Abschluss in Volkswirtschaftslehre. Seit 2009 ist der 53-Jährige bei den Asklepios Kliniken in Deutschland tätig, einem der grössten Klinikbetreiber Europas. Seit 2016 hat er dort die Funktion des CFO inne. Zuvor war er über 10 Jahre beim Prüfungs- und Beratungsunternehmen Pricewaterhouse Coopers mit Schwerpunkt Gesundheitswesen und begleitete unter anderem Universitätskliniken und Klinikgruppen in Wirtschaftsprüfungs- und Veränderungsprozessen. ...

April 29, 2026

Roland Mitterbauer wird stv. Chefredakteur der Stuttgarter Zeitung und Stuttgarter Nachrichten in Stuttgart; als Geschäftsführer der ZGS

Roland Mitterbauer wird stv. Chefredakteur der Stuttgarter Zeitung und Stuttgarter Nachrichten in Stuttgart; als Geschäftsführer der ZGS Roland Mitterbauer wird stv. Chefredakteur von StZ/StN | VSZV Verband Südwestdeutscher Zeitungsverleger e.V. 28 Apr.Roland Mitterbauer wird stv. Chefredakteur von StZ Roland Mitterbauer, bisher stellvertretender Chefredakteur und Head of Digital der Augsburger Allgemeinen, wird zum 01.07.2026 neuer stellvertretender Chefredakteur der Stuttgarter Zeitung und Stuttgarter Nachrichten sowie Geschäftsführer der Zeitungsgruppe Stuttgart GmbH (ZGS), einem Unternehmen der Neue Pressegesellschaft GmbH & Co. KG (NPG). ...

April 28, 2026

Wallenius Wilhelmsen ASA Annual General Meeting 2026 Norway; dividend authorisation through 2027

Wallenius Wilhelmsen ASA Annual General Meeting 2026 Norway; dividend authorisation through 2027 Annual General Meeting 2026 29 April 2026 Annual General Meeting 2026 Agenda Election of chairperson of the meeting Adoption of the notice and agenda Election of a person to co-sign the minutes Approval of the annual accounts and the annual report for the financial year 2025 Authorisation to the board of directors to distribute dividends under the Company’s dividend policy Approval of guidelines for salary and other remuneration to leading personnel Report on salary and other remuneration to leading personnel Statement on corporate governance pursuant to Section 2-9 of the Norwegian Accounting Act Approval of the fee to the Company’s auditor Election of members and deputy members to the board of directors Determination on the remuneration for the members of the board of directors Determination on the remuneration to the members of the nomination committee Determination on the remuneration to the members of the audit committee Determination on the remuneration to the members of the people, culture and remuneration committee Authorisation to the board of directors to acquire shares in the company Authorisation to the board of directors to increase the share capital The board of directors propose that the general meeting is chaired by Ylva Gjesdahl Petersen, lawyer at Advokatfirmaet Thommessen AS. Item 1 Election of chairperson of the meeting ...

April 28, 2026

Moritz Böcking leaves Klasmann-Deilmann GmbH; Jan Astrup appointed Managing Director

Moritz Böcking leaves Klasmann-Deilmann GmbH; Jan Astrup appointed Managing Director Klasmann-Deilmann: Change at the helm - Klasmann-Deilmann Klasmann-Deilmann: Change at the helm Moritz Böcking is leaving the company; Jan Astrup appointed Managing Director After fifteen years of successful collaboration, Managing Director Moritz Böcking and the Shareholders of Klasmann-Deilmann GmbH have mutually agreed to part ways. Effective 1 May 2026, Moritz Böcking will hand over his position as Managing Director to Jan Astrup, who previously served as Chief Operating Officer at the company in 2021 ...

April 28, 2026